SUNSCREEN PRODUCT AND PROCESS FOR THE PRODUCTION THEREOF

Abstract: A novel lipomelanin sunscreen complex includes melanin linked to a lipid to form a lipomelanin. One or more ultraviolet light absorbing compounds can be added to form a lipomelanin sunscreen complex. A method for making the complex includes the oxidization of DOPA in the presence of a lipid and one ore more ultraviolet absorbing compounds to form a mixture and precipitating the complex from the mixture by the addition of acid. The lipomelanin sunscreen complex provides protection against harmful ultraviolet radiation. The level of UV protection may be varied according to the presence and properties of the ultraviolet absorbing compounds in the complex.

Description: SUNSCREENPRODUCTAND PROCESS FORTHE PRODUCTION THEREOF TECHNICAL FIELD The present invention relates to novel sunscreen complexes incorporating melanin and melanin analogs and a method for making the complexes. In particular, the present invention relates to ultraviolet light absorbing compounds and lipids incorporated into a novel melanin- containing product. BACKGROUND ART Melanins are the major pigments of hair, skin and eyes. Naturally occurring melanins can be of a variety of colours, such as black, brown and red. Two major categories of melanins are known; eumelanins which provide a black or brown pigmentation, and pheomelanins, which provide a yellow to reddish-brown pigmentation. Natural suntanning occurs through exposure of the skin to light radiation at a wavelength of 280-400 nm. For most individuals the sensitivity of the skin to ultraviolet radiation (hereinafter referred to as "UVR") is largely determined by its melanin content. The amounts and types of melanin present in the skin vary from person to person and, thus, the tolerance of the skin when exposed to UVR varies from person to person. For most individuals the greater the melanin content of the skin of an individual, the more tolerant is the skin of that individual to UVR. Melanins are complex heteropolymers, of which the biosynthetic pathways and exact chemical structure are unknown. However, melanins are believed to be copolymers of 3,4-dihydroxyphenylalanine (DOPA) and cysteinyldopa. While the inventors do not intend to be limited to any particular scheme of synthesis, it is believed that the in vivo synthetic pathway leading to the production of melanin begins with the enzymatic oxidation of the amino acid, tyrosine, to form DOPA, and continues in the presence of the enzyme tyrosinase (polyphenol oxidase) with a series of oxidation and polymerization reactions to result in melanin. This postulated synthetic pathway may be represented as follows: TYROSINE DOPA DOPAQUINONE [CONTINUED ON NEXT PAGE] COOH I DOPAQUINONE CYSTEINE LEUC ODOPACHROME 5-S-CYSTEINYLDOPA BENZOTHIAZINE PHEOMELANINS DOPACHROME ,6-DIHYDROXYINDOLE EUMELANINS INDOLE-5,6-QUINONE Melanins may also be produced by the auto- oxidation of DOPA, whereby the production of melanin occurs in the absence of tyrosinase. Thus, it is believed that known melanins, or compounds with the same or similar functional features as known melanins, may be produced either naturally or synthetically from DOPA, analogs of DOPA or biosynthetic precursors of DOPA. As used herein, "melanins" includes all such known melanins or melanin products, however derived, and all melanin-like compounds or analogs with the herein-described pigment and photoprotective functions. The photoprotective function of melanin is believed to be associated with both its physical and biochemical properties. Melanin is believed to dissipate UVR into heat which is absorbed, and to promote oxidation reactions and quench free radicals, the formation of which is induced by UVR. Melanin is able to function as a stable free radical, thus resulting in its ability to quench damaging free radicals formed in the skin on exposure to UVR. The role of melanin as a free radical scavenger is significant in its photoprotective role in individuals having a moderate or greater melanin content in their skin; however, it is highly desirable that individuals having a minimal melanin content in their skin supplement the body's natural protective mechanism to UVR with a topical sunscreen supplement. It is now recognized that even individuals with moderate or greater levels of melanin should supplement this natural protective mechanism when longer exposure to UVR is anticipated. As a result of the increasing awareness of the public of the detrimental effects of exposure to UVR, a variety of sunscreen compositions for topical administration have been developed. Various salicylate compounds have been described as sunscreen agents due to their ability to absorb UVR. For example, United States patents 3,506,758 and 4,256,664 describe compositions for use as sunscreens which include the esterification product of p-aminobenzoic acid (paba) and/or salicylic acid with lecithins, choline and/or imidazoles having a reactive hydroxyl group. United States patent 4,454,112 describes tocopherol acetylsalicylate compounds which are useful as sunscreen agents in compositions for topical administration. However, it has been found that salicylate compounds may cause skin irritations and allergic reactions in some individuals, and, as a result, are not ideal as the primary components of such topical compositions. A common UVR absorbing compound found in sunscreen compositions is paba, and esters of paba, such as octyl dimethyl paba [octyl-p-(dimethyl-amino)benzoate]. United States patent 4,434,154 teaches one such UVR protective composition which contains an emulsion of octyl dimethyl paba, dihydroxy acetone, water, oil and a surfactant. Sun protectant compositions have also been described which contain melanin. However, the known methods of making melanin have disadvantages. With both the enzymatic and auto- oxidation methods for preparing melanins, the properties of the melanin product obtained make it undesirable for incorporation into a sunscreen composition for application onto the skin. Specifically, the melanins obtained are granular in nature, which results in a product that cannot be spread evenly when applied to the skin. These melanins are also undesirable in that they are insoluble under acceptable physiological skin conditions (i.e. neutral pH). Further, the effectiveness of these melanins is limited with respect to ultraviolet absorption. Specifically, the absorption capacity of the melanins produced by either of these methods is low in the short¬ wave range (UVB) of the ultraviolet spectrum. United States patent 4,806,344 describes one such melanin composition additionally comprising ferric chloride, triethanolamine, a sunscreen compound such as paba and a cosmetic base in the form of an oil, cream or ointment. Many of the sunscreen products currently available do not fully protect the skin against the complete wavelength spectrum of UVR. UVR comprises both long-wave UVR (or UVA, having a wavelength of approximately 320-400 nm) and short-wave UVR (or UVB, having a wavelength of approximately 290-320 nm). Of particular concern for a large portion of the population is protection of the skin against the aging process which is accelerated by exposure to UVR. Long-wave UVA is believed to specifically contribute to the aging process. Most ultraviolet light absorbing compounds useful as sunscreen agents only absorb within a small range of the wavelength of UVR. Thus, in order to maximize the absorption capacity of UVR in a sunscreen composition, the composition may contain not just a single sunscreen compound but several such compounds which are selected to provide broad range UVR protection. However, sunscreen compositions containing a variety of compounds are more apt to cause allergic or photoallergic reactions in individuals. Allergic and photoallergic reactions to existing sunscreen compounds and compositions is a common occurrence and generally results in dermatitis or photodermatitis. Certain individuals also suffer from skin eruptions due to long UVA and visible light, and a very broad wavelength sunscreen would be valuable for these people. Thus, it would be desirable to provide a sunscreen composition which imparts effective protection against the broad spectrum of UVR, which is compatible for use with human skin tissue. DISCLOSURE OF THE INVENTION It is an object of the present invention to provide novel melanin- containing compounds, and a method for making such compounds. Accordingly, in one aspect, the present invention provides a lipomelanin comprising a melanin compound linked to a lipid compound. In another aspect of the present invention, there is provided a lipomelanin sunscreen complex comprising a melanin compound linked to a lipid compound to form a lipomelanin, wherein said lipomelanin incorporates at least one ultraviolet light absorbing compound. In yet another aspect of the present invention, there is provided a method for making a lipomelanin complex comprising the steps of enzymatically converting 3,4-dihydroxyphenylalanine or a suitable analog thereof to melanin, in the presence of a lipid, and isolating the resulting lipomelanin. In a further aspect of the present invention, there is provided a method for making a lipomelanin sunscreen complex comprising a melanin compound linked to a lipid compound to form a lipomelanin wherein said lipomelanin encompasses at least one ultraviolet light absorbing compound, including the steps of enzymatically converting 3,4- dihydroxyphenylalanine or a suitable analog thereof to melanin, in the presence of a lipid and an ultraviolet light absorbing compound, and isolating the complex. The novel composition of the present invention comprises melanin linked to a lipid compound to form a lipomelanin. The lipomelanin of the present invention is a complex. The structure is not clearly understood, largely due to the lack of information about the synthesis and structure of melanins. As used herein, "lipomelanins" refers to the novel compounds of the present invention, comprising one or more lipids (as hereinafter more fully described) linked to one or more melanins. As used herein, "lipomelanin sunscreen complex" comprises a lipomelanin and an ultraviolet light absorbing compound. The lipomelanin sunscreen complex has been found to absorb UVR and particularly short-wave UVB to a greater extent than melanin. Moreover, the inclusion of an ultraviolet absorbing compound with the lipomelanin advantageously provides a sunscreen compound in which the absoφtion of both UVA and UVB may be varied by selecting and varying the number and properties of ultraviolet absorbing compound or compounds retained within the complex. Thus, a lipomelanin sunscreen complex having a high level of absoφtion of both UVA and UVB may be provided by incoφorating the appropriate UV-absorbing compounds into the lipomelanin. The characteristics of the lipomelanin or the lipomelanin sunscreen complex of the present invention make it suitable for application to the skin. Specifically, it has the consistency of a smooth cream and thus may be easily incoφorated into other creams for application to the skin. Its consistency also enables it to be spread evenly on the skin (either alone or in combination with other creams and ingredients) for uniform sunscreen protection. It is soluble at physiological pH making it suitable for application to human skin. Furthermore, it is less allergenic than other sunscreen compounds, thereby making it desirable for use by those having sensitive skin. In addition to the sunscreen and pigmentation functions of the lipomelanin and lipomelanin sunscreen complex, the compounds of the present invention may be useful for treatment of certain skin disorders such as hemangioma or vitiligo. Abnormal skin pigmentation and sensitivity to ultraviolet light are associated with these and other disorders, and the compounds of the present invention may function to provide additional pigmentation or standardization of existing pigmentation to skin while still maintaining protection from UVR. Additionally, the sunscreen and pigmentation aspects of the present invention make it suitable for use as a hair dye composition. The lipomelanin composition can be applied to the hair to provide increased pigmentation. BRIEF DESCRIPTION OF THE DRAWINGS Embodiments of the present invention will be described with reference to the following drawings in which: Figure 1 shows the absoφtion spectra of unoxidized DOPA, at the wavelengths of from 260 to 440 nm; Figure 2 shows the absoφtion spectra of melanin and lipomelanin; Figure 3 shows the absoφtion spectra of melanin, paba-melanin, parsol-melanin and paba-parsol-melanin in the absence of an incoφorated lipid; Figure 4 shows the absoφtion spectra of lipomelanin, paba- lipomelanin, parsol-lipomelanin and paba-parsol-lipomelanin; Figure 5 shows the absoφtion spectra of melanin, paba-melanin and parsol-melanin, where the paba and parsol are added after the oxidation step; Figure 6 shows the absoφtion spectra of lipomelanin, paba- lipomelanin and parsol-lipomelanin, where the paba and parsol are added after the oxidation step; Figure 7 shows the absoφtion spectra of lipomelanin (prepared with tyrosinase and by two preparation methods without tyrosinase); and Figure 8 shows the absoφtion spectra of lipomelanin with acetylsalicylic acid and either paba or benzophenone. BEST MODE FOR CARRYING OUT THE INVENTION In accordance with one aspect of the invention, a lipomelanin is disclosed. The lipomelanin is a complex prepared by oxidization of DOPA or a suitable DOPA analog in the presence of a lipid compound (as hereinafter more fully described). The lipomelanin is creamy and smooth, suitable for application to human skin. In a further aspect of this invention, a lipomelanin sunscreen complex is provided. The complex comprises melanin linked to a lipid compound to form a lipomelanin, with which one or more ultraviolet light absorbing compounds may be associated. The complex thus provides protection from the harmful aspects of UVR, while additionally adding pigmentation to the skin of the user of the complex. The term "lipid" as used herein is meant to encompass compounds classified as lipids including fats, phospholipids and fatty acids. Lipids are organic compounds chiefly comprising carbon, hydrogen and oxygen, but may also include other elements. Lipids are insoluble in water, but are soluble in various organic solvents. Included within the lipid family are fats, which are esters of glycerol which hydrolyze to form glycerol and fatty acids. Fatty acids are organic acids comprising carbon and hydrogen and including a carboxyl group. Phospholipids are similar to fats in which one fatty acid component has been replaced by a phosphoric acid component, and may additionally contain nitrogen. Non-limiting examples of lipids for use as the lipid compound in the lipomelanin sunscreen complex of the present invention include saturated and unsaturated fatty acids; triglycerides; diglycerides; monoglycerides; methyl, ethyl, octyl, and higher molecular weight esters of fatty acids; lecithins (for example phosphatidyl choline); cephalins (for example , phosphatidyl ethanolamine) ; phosphatidyl dimethylethanolamine; phosphatidyl momomethylethanolamine; phosphatidyl inositol, phosphatidyl serine and phosphatidic acid. Preferably, the lipids of the present invention should be of high molecular weight, with an approximate lower limit of a C 10 chain length. Preferred fatty acids include but are not limited to long-chain fatty acids such as palmitic acid, stearic acid, arachidonic acid, oleic acid, linoleic acid and linolenic acid. Preferred phospholipids for use as the lipid compound in the lipomelanin sunscreen complex include lecithins. The lipomelanin sunscreen complex may incoφorate more than one ultraviolet light absorbing compound. In this way, the effectiveness of the complex may be maximized by incoφorating within the complex compounds which absorb in different wavelengths of the ultraviolet spectrum, for example, in both the short-wave UVB and in the long- wave UVA regions of the UVR spectrum. The ultraviolet light absorbing compound may be any compound which absorbs ultraviolet radiation and is suitable for application onto the skin. The United States FDA has disseminated a list of sunscreen and sunblocking agents considered safe and effective for both UVA and UVB. Non-limiting examples of such suitable ultraviolet absorbing compounds for incoφoration into the lipomelanin sunscreen complex include paba, butyl paba, cinoxate, diethanolamine p-methoxycinnamate, digalloyl trioleate, dioxybenzone, amyl dimethyl paba, homomenthyl salicylate, ethyl 4-aminobenzoate, ethyl 4-[bw(hydroxypropyl)] aminobenzoate, 2-Ethyl-hexyl 2-cyano-3,3-dephenylacrylate, ethyl-hexyl p-methoxycinnamate, 2-Ethyl-hexyl salicylate, glycerol aminobenzoate, homosalate, lawsone with dihydroxyacetone, menthyl anthranilate, Padimate A, Padimate O, 2-Phenylbenzimidazole 5-sulfonic acid, red petrolatum, acetylsalicylic acid, triethanolamine salicylate, octyl dimethyl paba, glycerol paba, 2-hydroxy-4-methoxy-5-sulfobenzophenone (trihydrate) (Sulisobenzone), butyl methoxy benzoyhnethane (Parsol 1789), 4-tert-butyl-4'-methoxy-dibenzoylmethane, 2-hydroxy-4- methoxybenzophenone (oxybenzone), isoamyl dimethyl paba ester, 4- hydroxycinnamic acid, benzophenone, and polymers or combinations thereof. Non-limiting examples of compounds appropriate for incoφoration into the complex and known to specifically absorb UVA include oxybenzone, sulisobenzone, dioxybenzone, menthyl anthranilate and Parsol 1789. Non-limiting examples of compounds appropriate for incoφoration into the complex and known to absorb UVB include paba, amyl dimethyl paba, glyceryl paba, octyl dimethyl paba, anthranilates, 2-ethoxyethyl p- methoxycinnamate, diethanolamine p-methoxycinnamate, digalloyl trioleate, ethyl 4-bw-(hydroxypropyl) aminobenzoate, 2-Ethyl-hexyl salicylate, glycerol aminobenzoate, homomenthyl salicylate, lawsone with dihydroxyacetone, 2-Phenyl benzimidazole 5-sulfonic acid and triethanolamine salicylate. The method for making the melanin sunscreen complex of the present invention includes oxidizing 3,4-dihydroxyphenylalanine (DOPA) to form melanin. Analogs of DOPA may also be used in accordance with the present invention. Suitable analog compounds may include synthetic analogs or naturally occurring analogs. Non-limiting examples of DOPA analogs include hydroquinone, cathechol, o-quinone, p-quinone, DOPA methyl ester, dihydroxyphenylacetic acid, dihydroxyphenyl glycol and dihydroxyphenyl serine. DOPA or an analog thereof may be oxidized by aeration. Thus, for example, air is bubbled through a solution of DOPA in an alkaline medium. The solution may also be aerated by rotary movement or shaking. The pH of the alkaline medium may be in the range of from about 7 to about 10. Preferably, the alkaline medium has a pH of about 8. Non-limiting examples of a suitable alkaline medium include sodium phosphate, potassium phosphate, sodium borate, and tris-hydroxy methyl- HC1. Most preferably, the alkaline medium is sodium phosphate buffer at pH 8.0. The lipid compound, either alone or in conjunction with one or moree ultraviolet absorbing compounds are added to the DOPA solution and aeration on a rotary shaker is continued for a time sufficient to oxidize DOPA to form lipomelanin, at least overnight. In another aspect of the present invention, the melanin may be enzymatically oxidized by tyrosinase. Tyrosinase oxidation occurs at an approximate pH of 6.8, at temperatures of between 20°C and 37°C. Upon completion of the oxidation, the resulting lipomelanin formed is precipitated by addition of inorganic acid to the solution. The acid is not particularly restricted and may include any acid capable of reducing the pH of the final suspension to a pH sufficient for precipitation of the complex, typically below 4, such as hydrochloric acid or sulphuric acid. The precipitated melanin complex is removed from the solution by any method suitable for separating solids from liquids. Centrifugation as well as filtration are methods suitable to separate the melanin complex from the acid medium. In order to purify the melanin complex, the complex may be redissolved in a suitable alkaline medium, as set out in the foregoing, and precipitated therefrom by the addition of acid. These purification steps are preferably repeated at least twice in order to remove impurities from the complex. The absoφtion spectra of the novel compounds prepared according to the method of the present invention are noted in the Figures. By way of reference, Figure 1 shows the absoφtion spectra, at wavelengths of from 260 to 440 nm, of unoxidized DOPA, together with a blank. Figure 2 presents the absoφtion spectra of melanin (oxidized from DOPA, without any lipid compounds) and the lipomelanin of the present invention, without any incoφorated ultraviolet light absorbing compound. As can be noted from Figure 2, melanin has an increased ability to absorb UVR over a broader range of wavelengths than does the unoxidized DOPA of Figure 1. The lipomelanin of the present invention provides a UVR absorbance profile and quantity similar to that of melanin. Figure 3 shows the absoφtion spectra of various melanins with ultraviolet light absorbing compounds. No lipid is included. The figure shows the spectra of: (a) melanin, (b) paba-melanin, (c) parsol-melanin and (d) paba-parsol melanin. Figure 4 is the absoφtion spectra of the lipomelanins of the present invention as follows: (a) lipomelanin without any ultraviolet light absorbing compounds, (b) paba-lipomelanin, (c) parsol-lipomelanin and (d) paba-parsol lipomelanin. Figures 5 and 6 show the absoφtion spectra of various melanins and lipomelanins wherein the additional copounds (lipids and ultraviolet light absorbing compounds) are added to the melanin mixture after the oxidation. As can be seen from Figures 5 and 6, the addition of compounds after oxidation results in melanin mixtures having lesser and flatter absoφtion spectra than the melanin mixtures of Figures 3 and 4 where the additional compounds are incoφorated into the melanin at the time of oxidation. Figure 7 provides a comparison of lipomelanins prepared by the enzymatic oxidation of DOPA or oxidation of DOPA by aeration. Figure 8 shows the absoφtion spectra of melanins of the present invention prepared by various procedures. These include (a) lipomelanin with ASA prepared via enzymatic conversion of DOPA, (b) lipomelanin with ASA prepared via aeration without tyrosinase, (c) lipomelanin with ASA and paba prepared by aeration without tyrosinase, and (d) lipomelanin with ASA and benzophenone prepared via aeration with tyrosinase. As can be seen from Figure 8, the incoφoration of ASA was increased using the aeration process of the present invention. Both paba and ASA were incoφorated into the lipomelanin, although benzophenone is not incoφorated in large amounts, and may also act to reduce ASA incoφoration, due to its relative insolubility in water. The textural characteristics of the lipomelanin sunscreen complex of the present invention make it suitable for application directly onto the skin. The lipid component of the lipomelanin allows adherence of the composition to the skin. In addition, the lipomelanin of the present invention is creamy and smooth at physiological pH, and suitable for topical application. The complex may be combined with other ingredients to form a sunscreen composition. These ingredients may include substances typically found within creams, oils, ointments and lotions applied to the skin. Further, the added ingredients may function simply as diluents, or may optionally function to integrate additional utility into the composition. Coloring agents that may impart some additional ultraviolet light protective value may also be added such as zinc oxide or titanium dioxide. Non-limiting examples of suitable ingredients for incoφoration into such a composition include oils, such as mineral oil, jojoba oil and mink oil, emollients, vitamins, fragrances, dyes, colouring agents, pigments, water and any other ingredients typically added to skin-care compositions. Aspects of the present invention will now be described by reference to the following specific non-limiting examples. Example 1 : Enzymatic Preparation of Lipomelanin from DOPA A solution containing 200 mg DOPA, 0.2 ml linoleic acid (0.642 mmoles, Sigma Chemical Company) and 20 mg purified mushroom tyrosinase (3,310 - 3,870 units/mg, Sigma Chemical Company) in 50 ml 0.05 M phosphate buffer (pH 6.8) was incubated with shaking and exposure to air at 37°C for 16 hours. The lipomelanin was acidified to pH 3 and 1.0 M and sedimented by centrifugation at 1 ,000 g for 10 min. The supernatant was discarded and the melanin was dissolved in 10 ml 0.1 M sodium hydroxide solution. The lipomelanin was precipitated by adding 1.0M hydrochloric acid to pH 3.0. The lipomelanin was then sedimented by centrifugation at 1 ,000 g f or 10 minutes. The lipomelanin was redissolved and resedimented by centrifugation following the same procedure three times more. The lipomelanin was then suspended in 5 ml water, and stored at 4°C until further use. Example 2: Preparation of Lipomelanin by Autooxidation of DOPA A solution containing 500 mg DOPA and 0.5 ml linoleic acid (Sigma Chemical Company) in 250 ml 0.1 M phosphate buffer at pH 8.0 was prepared. Air was bubbled through the solution at room temperature (approximately 21 °C) for 16 hours. The lipomelanin was isolated by sedimenting, redissolving and resedimenting as described in Example 1. Increased yields of lipomelanin can be achieved by autooxidation of DOPA using the following procedure. A solution containing 200 mg DOPA in 50 ml 0.1M phosphate buffer at pH 8.0 was aerated by bubbling air through the solution at room temperature for 3 hours. 0.2 ml linoleic acid was then added and aeration continued for a further sixteen hours. The lipomelanin was isolated by sedimenting, redissolving and resedimenting as described in Example 1. Example 3: Preparation of Lipomelanin with Additional Compounds A solution containing 0.5 g DOPA in 250 ml 0.1 M phosphate buffer at pH 8.0 was prepared. Air was bubbled through the solution at room temperature (approximately 21 °C) for 3 hours. 0.5 ml linoleic acid and 0.5 g paba were added. Aeration continued for an additional 12 hours. The lipomelanin complex was isolated by sedimentation, redissolving, and resedimenting as described in Example 1. The lipomelanin complex prepared according to Example 3 is creamy and smooth for use in accordance with the sunscreen compositions of the present invention. It is more soluble in water at neutral pH than melanins alone, and soluble for use in accordance with the sunscreens of the present invention. Absoφtion properties of the lipomelanin in the range of short wavelength UVB is high, as indicated in Figure 4. Example 4: Preparation of Lipomelanin with Lecithin A solution containing 200 mg DOPA, 0.642 mmoles lecithin and 20 mg purified mushroom tyrosinase (3,310 - 3,870 units/mg, Sigma Chemical Company) in 50 ml 0.05 M phosphate buffer (pH 6.8) was incubated with shaking and exposure to air at 37°C for 16 hours. The lipomelanin was acidified to pH 3.0 and 1.0 M and sedimented by centrifugation at 1 ,000 g for 10 min. The supernatant was discarded and the lipomelanin was dissolved in 10 ml 0.1 M sodium hydroxide solution. The lipomelanin was precipitated by adding 1.0 M hydrochloric acid to pH 3.0. The melanin was then sedimented by centrifugation at 1 ,000 g for 10 minutes. The lipomelanin was redissolved and resedimented by centrifugation following the same procedure three times more. The lipomelanin was then suspended in 5 ml water, and stored at 4°C until further use. Example 5: Preparation of Lipomelanins with Two Ultraviolet light Absorbing Compounds. A solution containing 200 mg (1.01 mmole) DOPA, in 50 ml P0 4 buffer at pH 8.0 was aerated by shaking for three hours at room temperature. 500 mg of paba (3.65 mmoles) in 45 ml of P0 4 buffer and 0.2 ml (0.642 mmoles) linoleic acid and 0.4 ml (2.38 mmoles) cinnamic acid ethyl ester were then added. Aeration continued for a further 16 hours. The lipomelanin complex was isolated as described in Example 1. An alternate lipomelanin sunscreen complex incoφorating paba and parsol was prepared as follows. A solution containing 200 mg (1.01 mmole) DOPA, in 50 ml P0 4 buffer at pH 8.0 was aerated by shaking for three hours at room temperature. 500 mg of paba (3.65 mmoles) in 45 ml of P0 4 buffer and 0.2 ml (0.642 mmoles) linoleic acid and 0.2 ml Parsol 1789 were then added. Aeration continued for a further 16 hours. The lipomelanin complex was isolated as described in Example 1. The absoφtion spectrum of the resulting compound (paba-parsol-melanin) is shown in Figure 4. Other embodiments or variations are possible within the sphere and scope of the present invention. All such modifications and variations are believed to be within the sphere and scope of the present invention as defined by the claims appended hereto.

Claims: What is claimed is: 1. A lipomelanin compound comprising a melanin linked to a lipid. 2. The lipomelanin compound defined in claim 1 , wherein the lipid is selected from the group comprising fats, phospholipids, fatty acids and mixtures thereof. 3. The lipomelanin compound defined in claim 1, wherein the lipid is selected from the group comprising saturated and unsaturated fatty acids, triglycerides, diglycerides, monoglycerides, esters of fatty acids, lecithins, cephalins, phosphatdiyl ethanolamine, phosphatidyl dime thy lethanolamine, phosphatidyl momomethylethanolamine, phosphatidyl inositol, phosphatidyl serine, phosphatidic acid and mixtures thereof. 4. The lipomelanin compound defined in claim 2, wherein the fatty acid is selected from the group comprising palmitic acid, stearic acid, arachidonic acid, oleic acid, linoleic acid, linolenic acid and mixtures thereof. 5. The lipomelanin compound defined in claim 1 , wherein the lipid is lecithin. 6. The lipomelanin compound defined in claim 1 , wherein the lipid is linoleic acid. 7. A lipomelanin sunscreen complex comprising a melanin compound linked to a lipid to form a lipomelanin, and wherein said lipomelanin encompasses at least one ultraviolet light absorbing compound. 8. The lipomelanin sunscreen complex defined in claim 7, wherein the lipid is selected from the group comprising fats, phospholipids, fatty acids and mixtures thereof. 9. The lipomelanin sunscreen complex defined in claim 7, wherein the lipid is selected from the group comprising saturated and unsaturated fatty acids, triglycerides, diglycerides, monoglycerides, esters of fatty acids, lecithins, cephalins, phosphatdiyl ethanolamine, phosphatidyl dime thy lethanolamine, phosphatidyl momomethylethanolamine, phosphatidyl inositol, phosphatidyl serine, phosphatidic acid and mixtures thereof. 10. The lipomelanin sunscreen complex defined in claim 8, wherein the fatty acid is selected from the group comprising palmitic acid, stearic acid, arachidonic acid, oleic acid, linoleic acid, linolenic acid and mixtures thereof. 11. The lipomelanin sunscreen complex defined in claim 7, wherein the lipid is lecithin. 12. The lipomelanin sunscreen complex defined in claim 7, wherein the lipid is linoleic acid. 13. The lipomelanin sunscreen complex defined in claim 7, wherein the ultraviolet light absorbing compound is selected from the group comprising paba, butyl paba, cinoxate, diethanolamine p- methoxycinnamate, digalloyl trioleate, dioxybenzone, amyl dimethyl paba, homomenthyl salicylate, ethyl 4-aminobenzoate, ethyl 4- [bw(hydroxypropyl)] aminobenzoate, 2-Ethyl-hexyl 2-cyano-3,3- dephenylacrylate, ethyl-hexyl p-methoxycinnamate, 2-Ethyl-hexyl salicylate, glycerol aminobenzoate, homosalate, lawsone with dihydroxyacetone, menthyl anthranilate, Padimate A, Padimate O, 2- Phenylbenzimidazole 5-sulfonic acid, red petrolatum, acetylsalicylic acid, triethanolamine salicylate, octyl dimethyl paba, glycerol paba, 2-hydroxy- 4-methoxy-5-sulfobenzophenone (trihydrate) (Sulisobenzone), butyl methoxy benzoyhnethane (Parsol 1789), 4-tert-butyl-4'-methoxy- dibenzoyhnethane, 2-hydroxy-4-methoxybenzophenone (oxybenzone), isoamyl dimethyl paba ester, 4-hydroxycinnamic acid, benzophenone, polymers and mixtures thereof. 14. The lipomelanin sunscreen complex defined in claim 8, wherein the lipid is linoleic acid and the ultraviolet light absorbing compound is paba. 15. The lipomelanin sunscreen complex defined in claim 8, wherein the lipid is linoleic acid and the ultraviolet light absorbing compounds are paba and parsol. 16. A topical sunscreen composition comprising the lipomelanin sunscreen complex defined in any one of claims 7-15, in combination with at least one adjuvant acceptable for application to the human skin. 17. The topical sunscreen composition defined in claim 16, further comprising at least one member selected from the group comprising mineral oil, jojoba oil, mink oil, emollients, vitamins, fragrances, dyes, colouring agents, pigments, water and mixtures thereof. 18. A method for making lipomelanin comprising the steps of: (i) oxidizing 3,4-dihydroxyphenylalanine or a suitable analog thereof in an alkaline medium in the presence of a lipid; and (ii) isolating the resulting lipomelanin. 19. The method defined in claim 18, wherein the 3,4- dihydroxyphenylalanine or suitable analog thereof is oxidized by aeration. 20. A method for making lipomelanin comprising the steps of: (i) enzymatically converting 3,4-dihydroxyphenylalanine or a suitable analog thereof to melanin, in the presence of a lipid; (ii) isolating the resulting lipomelanin. 21. The method defined in claim 20, wherein the enzyme for conversion of 3,4,-dihydroxyphenylalanine is tyrosinase. 22. The method defined in claim 18 or 20, in which the isolation of lipomelanin is by acid precipitation of the lipomelanin. 23. The method defined in claim 22, wherein the acid used to precipitate the lipomelanin is selected from the group consisting of hydroxhloric acid and sulfuric acid. 24. A method for making a lipomelanin sunscreen complex comprising the steps of: (i) oxidizing 3,4-dihydroxyphenylalanine or a suitable analog thereof in an alkaline medium in the presence of a lipid and at least one ultraviolet light absorbing compound; and (ii) isolating the complex. 25. The method defined in claim 24, wherein the 3,4- dihydroxyphenylalanine or suitable analog thereof is oxidized by aeration. 26. A method for making a lipomelanin sunscreen complex comprising the steps of: (i) enzymatically converting 3,4-dihydroxyphenaline or a suitable analog thereof to melanin, in the presence of a lipid and at least one ultraviolet light absorbing compound; and (ii) isolating the complex. 27. The method defined in claim 26, wherein the enzyme for conversion of 3,4,-dihydroxyphenylalanine is tyrosinase. 28. The method defined in claim 24 or 26, wherein the isolation of the complex is by acid precipitation of the complex. 29. The method defined in claim 28, wherein the acid used to precipitate the complex is selected from the group comprising hydrochloric acid, sulfuric acid and mixtures thereof. 30. The method defined in any one of claims 18, 21, 24 and 26, wherein the lipid is selected from the group comprising fats, phospholipids, fatty acids and mixtures thereof. 31. The method defined in any one of claims 18, 21, 24 and 26, wherein the lipid is selected from the group comprising saturated and unsaturated fatty acids, triglycerides, diglycerides, monoglycerides, esters of fatty acids, lecithins, cephalins, phosphatdiyl ethanolamine, ph o s ph ati d y l d i me th yl e th an o l amin e , ph o s ph ati dyl momomethylethanolamine, phosphatidyl inositol, phosphatidyl serine, phosphatidic acid and mixtures thereof. 32. The method defined in claim 31 , wherein the fatty acid is selected from the group comprising palmitic acid, stearic acid, arachidonic acid, oleic acid, linoleic acid, linolenic acid and mixtures thereof. 33. The method defined in claim 31, wherein the lipid is lecithin. 34. The method defined in claim 24 or 26, wherein the ultraviolet light absorbing compound is selected from the group comprising paba, butyl paba, cinoxate, diethanolamine p-methoxycinnamate, digalloyl trioleate, dioxybenzone, amyl dimethyl paba, homomenthyl salicylate, ethyl 4-aminobenzoate, ethyl 4-[bw(hydroxypropyl)] aminobenzoate, 2- Ethyl-hexyl 2-cyano-3 ,3-dephenylacrylate, ethyl-hexyl p- methoxycinnamate, 2-Ethyl-hexyl salicylate, glycerol aminobenzoate, homosalate, lawsone with dihydroxyacetone, menthyl anthranilate, Padimate A, Padimate O, 2-Phenylbenzimidazole 5-sulfonic acid, red petrolatum, acetylsalicylic acid, triethanolamine salicylate, octyl dimethyl paba, glycerol paba, 2-hydroxy-4-methoxy-5-sulfobenzophenone (trihydrate) (Sulisobenzone), butyl methoxy benzoyhnethane (Parsol 1789), 4-tert-butyl-4'-methoxy-dibenzoylmethane, 2-hydroxy-4- methoxybenzophenone (oxybenzone), isoamyl dimethyl paba ester, 4- hydroxycinnamic acid, benzophenone, polymers and mixtures thereof. 35. The method defined in claim 24 or 26, wherein the lipid is linoleic acid and the ultraviolet light absorbing compound is paba. 36. The composition defined in any one of claims 11-17, for use in the treatment of abnormal skin pigmentation disorders or ultraviolet light hypersensitivity disorders. 37. The composition defined in any one of claims 11-17, for use as a hair dye.

Inventors: HABERMAN HERBERT F, MENON I ARAVINDAKSHAN, HABERMAN, HERBERT, F., MENON, I., ARAVINDAKSHAN
Applicants: DUSA PHARMACEUTICALS INC, DUSA PHARMACEUTICALS, INC.
Application year: 1994
Main classification: C09B69
IPC codes: A61K8, A61Q17, C09B69